CMS Off-Label Cancer Drug Policy Will Have “Very Narrow” Focus
The Centers for Medicare & Medicaid Services' pending policy decision on coverage of off-label cancer drugs will have a "very narrow" focus, Coverage & Analysis Group Director Steve Phurrough, MD, told the Schwab Soundview Washington Research Group health care conference May 6
You may also be interested in...
CMS' outcomes research priorities include developing real world data on the effectiveness of drugs in seniors, agency Administrator Mark McClellan told an American Medical Association conference in Washington, D.C. March 30
Idec's experience securing Medicare reimbursement for Zevalin should be considered the model for how coverage decisions will work for new products once Part B payment reforms are implemented in 2005, former CMS Administrator Tom Scully said
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011